Jimenez-Sainz Judit, Krysztofiak Adam, Garbarino Jennifer, Rogers Faye, Jensen Ryan B
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States.
Front Genet. 2022 May 30;13:884210. doi: 10.3389/fgene.2022.884210. eCollection 2022.
The BRCA2 germline missense variant, R3052W, resides in the DNA binding domain and has been previously classified as a pathogenic allele. In this study, we sought to determine how R3052W alters the cellular functions of BRCA2 in the DNA damage response. The BRCA2 R3052W mutated protein exacerbates genome instability, is unable to rescue homology-directed repair, and fails to complement cell survival following exposure to PARP inhibitors and crosslinking drugs. Surprisingly, despite anticipated defects in DNA binding or RAD51-mediated DNA strand exchange, the BRCA2 R3052W protein mislocalizes to the cytoplasm precluding its ability to perform any DNA repair functions. Rather than acting as a simple loss-of-function mutation, R3052W behaves as a dominant negative allele, likely by sequestering RAD51 in the cytoplasm.
BRCA2种系错义变体R3052W位于DNA结合域,此前已被归类为致病等位基因。在本研究中,我们试图确定R3052W如何改变BRCA2在DNA损伤反应中的细胞功能。BRCA2 R3052W突变蛋白加剧了基因组不稳定性,无法挽救同源定向修复,并且在暴露于PARP抑制剂和交联药物后无法补充细胞存活能力。令人惊讶的是,尽管预期在DNA结合或RAD51介导的DNA链交换方面存在缺陷,但BRCA2 R3052W蛋白却错误定位于细胞质,从而排除了其执行任何DNA修复功能的能力。R3052W并非作为简单的功能丧失突变起作用,而是可能通过将RAD51隔离在细胞质中而表现为显性负等位基因。